Trial · NCT02466243
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) From Baseline in Part A. | Lenabasum | -8.0 | Standard Error 8.16 | CDASI Activity Score | |
| Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) From Baseline in Part A. | Placebo | -5.5 | Standard Error 5.56 | CDASI Activity Score | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Lenabasum | Any TEAE | 11 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Placebo | Any TEAE | 8 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Lenabasum | Any serious TEAE | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Placebo | Any serious TEAE | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Lenabasum | Any TEAE leading to discontinuation | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Placebo | Any TEAE leading to discontinuation | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Lenabasum | Any severe TEAE | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Placebo | Any severe TEAE | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Lenabasum | No TEAE | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability | Placebo | No TEAE | 3 | Participants | |
| Change in Patient-reported Outcomes From Baseline at 84 Days for Part A | Placebo | -5.5 | Standard Error 5.56 | CDASI Damage Score | |
| Change in Patient-reported Outcomes From Baseline at 84 Days for Part A | Lenabasum 20 mg BID | -8.0 | Standard Error 8.16 | CDASI Damage Score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02466243/results